PD-1/PD-L1 inhibitors
Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
1. A compound which is:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
3. The pharmaceutical composition of claim 2 , further comprising one or more additional therapeutic agents.
4. The pharmaceutical composition of claim 3 , wherein the additional therapeutic agent is an anticancer agent selected from nivolumab, pembrolizumab, atezolizumab, and ipilimumab.
5. A method for treating hepatitis B virus comprising administering a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof, to a patient in need thereof.